Glyscend Ther­a­peu­tic­s' ear­ly da­ta show poly­mer mim­ics ben­e­fits of surgery in type 2 di­a­betes, obe­si­ty

Glyscend Ther­a­peu­tics re­leased topline da­ta for its poly­mer tar­get­ing type 2 di­a­betes and obe­si­ty to­day, with the hopes the can­di­date will have the same ef­fects as bariatric surgery with­out com­pli­ca­tions from the in­va­sive stan­dard-of-care pro­ce­dures.

The oral gut-tar­get­ing poly­mer, dubbed GLY-200, showed sig­nif­i­cant and clin­i­cal­ly rel­e­vant re­duc­tions in glu­cose af­ter eat­ing and a de­crease in body weight and food in­take in the 51 par­tic­i­pants in the com­pa­ny’s Phase IIa tri­al. Pa­tients took ei­ther the poly­mer or a place­bo twice dai­ly for 14 days.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.